Victoza (generic liraglutide) 1 pen

Liraglutide is a anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

It improves control of blood glucose. In patients with high cardiovascular risk, liraglutide has been shown to reduce the risk for first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. ADA guidelines currently consider liraglutide a first line pharmacologic therapy for type 2 diabetes (usually together with metformin), specifically for patients with atherosclerotic cardiovascular disease or obesity. A 2021 Cochrane review showed a HbA1c reduction of 0.24% more with liraglutide 1.8mg compared to insulin glargine, 0.33% more than exenatide 10µg twice daily, sitagliptin and rosiglitazone. In an RCT comparing liraglutide, glargine, glimepiride, and sitagliptin (all added to metformin) with a follow-up of 5 years, glargine and liraglutide were modestly more effective in achieving and maintaining target HbA1c, with no difference in outcomes of microvascular and cardiovascular disease.
Liraglutide may also be used together with diet and exercise for chronic weight management in adults. It has been shown to lead to greater weight loss than other glucagon-like peptide analogues.